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Abstract
Many components of Wnt/b-catenin signaling pathway also play critical roles in mammary tumor development, yet the role of
the tumor suppressor gene APC (adenomatous polyposis coli) in breast oncongenesis is unclear. To better understand the role
of Apc in mammary tumorigenesis, we introduced conditional Apc mutations specifically into two different mammary
epithelial populations using K14-cre and WAP-cre transgenic mice that express Cre-recombinase in mammary progenitor cells
and lactating luminal cells, respectively. Only the K14-cre–mediated Apc heterozygosity developed mammary adenocarci-
nomas demonstrating histological heterogeneity, suggesting the multilineage progenitor cell origin of these tumors. These
tumors harbored truncation mutation in a defined region in the remaining wild-type allele of Apc that would retain some
down-regulating activity of b-catenin signaling. Activating mutations at codons 12 and 61 of either H-Ras or K-Ras were also
found in a subset of these tumors. Expression profiles of acinar-type mammary tumors from K14-cre; Apc
CKO/+ mice showed
luminal epithelial gene expression pattern, and clustering analysisdemonstratedmore correlation to MMTV-neumodel than to
MMTV-Wnt1. In contrast, neither WAP-cre–induced Apc heterozygous nor homozygous mutations resulted in predisposition to
mammary tumorigenesis, although WAP-cre–mediated Apc deficiency resulted in severe squamous metaplasia of mammary
glands. Collectively, our results suggest that not only the epithelial origin but also a certain Apc mutations are selected to
achieve a specific level of b-catenin signaling optimal for mammary tumor development and explain partially the colon- but
not mammary-specific tumor development in patients that carry germline mutations in APC.
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Introduction
Breast cancer is one of the most common malignancies in women
in Western countries and it is the cause of death in approximately
20% of all females who die from cancer. Breast epithelium is a
dynamic organ capable of rapid proliferation and functional
differentiation upon pregnancy and lactation, followed by involu-
tion and remodeling at the end of each lactation period. The adult
mammary gland consists of secretory alveoli organized into lobules
and interconnected by a system of branching ducts. The entire
mammary epithelium is enveloped by a basement membrane and
embedded in a fatty connective tissue called the mammary fat pad.
In the ducts and alveoli, the mammary epithelium is organized into
two layers, a basal layer of myoepithelial cells and a luminal
epithelial layer. The myoepithelial cells, like other basal epithelial
cells, express basal keratins (in particular, K5 and K14), P-cadherin,
and the transcription factor p63 [1]. They also contain smooth
muscle-specific proteins, including the a-smooth muscle actin (a-
SMA), which confer contractility. By contrast, luminal cells express
K8 and K18, which are characteristics of simple epithelia and when
fully differentiated, secrete milk proteins [1].
The molecular mechanisms of the initiation of breast cancer are
well studied. Mutations in BRCA1 and BRCA2 result in increased
susceptibility to breast cancer [2] and mutations in TP53 are found
to be common in late stages of this cancer [3]. It has been shown
that dysregulation of the Wnt signaling pathway is an important
contributor to the initiation of breast cancer [4]. Adenomatous
Polyposis Coli (APC) is a member of the Wnt/b-catenin signaling
pathway that is involved in the maintenance of the progenitor cell
population in the skin, intestine and other tissues. Mutations and/
or altered expression in the tumor suppressor gene APC are
frequently found in sporadic breast cancers [5–7] which implicates
its role as a tumor suppressor in mammary epithelium. In mouse,
activation of Wnt/b-catenin signaling in the mammary epithelium
either by mutation in Apc (GenBank NM_007462) or by
stabilization of b-catenin (NM_007614), contributes to tumori-
genesis. For example, mice heterozygous for germline mutation in
Apc (Apc
Min) spontaneously develop mammary tumors, although at
a significantly lower incidence than intestinal tumors [8].
Transient expression of an activated form of b-catenin in secretory
luminal epithelium driven by the MMTV promoter leads to both
mammary gland hyperplasia and mammary adenocarcinoma [9].
Similarly, expression of a transcriptionally active form of b-catenin
lacking the N-terminal 89 amino acids (DN89 b-catenin) results in
precocious development, differentiation, and neoplasia in both
male and female mouse mammary glands [10]. The K5 promoter-
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(DN57 b-catenin) in the basal epithelial layer of the mammary
gland, led to basal-type mammary hyperplasia and invasive
carcinomas [11]. Contrasting results have been obtained when
Wnt/b-catenin signaling pathway was stably activated constitu-
tively in luminal cells of mammary epithelium using Cre-loxP
technology. The stabilization of b-catenin, aided either by Cre-
mediated oncogenic activation of b-catenin or Apc deficiency,
induced transdifferentiation into epidermis and squamous meta-
plasia of the mammary epithelium but failed to induce neoplasia
[12,13]. Apc deficient luminal epithelium developed acanthomas
only in the additional absence of Tcf-1 [13]. Together, these
results indicate a key role for Apc in both mammary gland
development and tumorigenesis, most likely through activation of
b-catenin signaling, but it is still unclear why the variation in
methods of b-catenin signaling activation can produce different
phenotypes in mammary glands. These results suggest that the
timing and the cell types in which the Apc mutations occur might
be important for breast cancer development.
To better understand how Apc inactivation in the mammary
epithelium results in cancer, we crossed mice carrying a floxed allele
of Apc to K14-cre and whey acid protein (WAP)-cre transgenic mice.
K14-expression starts embryonically in cellsthat give riseto both basal
and luminal cells of mammary gland, while WAP expression is
restricted to adult females following pregnancy and lactation. We
show here that K14-mediated Apc heterozygosity directly resulted in
mammary adenocarcinoma development, but WAP-mediated Apc
deficiency resulted in severe squamous metaplasia and not readily in
neoplasia. The expression of both luminal and myoepithelial lineage
markers, as well as the presence of the common initiating somatic Apc
mutation in histologically distinct regions of a tumor, is in line with
the progenitor cell origin of K14-cre; Apc
CKO/+ tumors. The remaining
wild-type allele of Apc in these tumors harbored truncation mutation
in a specific region of the gene, which seems to be selected for
mammary tumorigenesis. These results show that the timing and cell
type in which the critical mutational events occur and the level of
resultant activation of the b-catenin signaling cascade are critical for
the initiation of mammary tumor development.
Results
Mammary Tumor Susceptibility in K14-Cre; Apc
CKO/+ Mice
but Not in WAP-Cre–Induced Apc Mutant Mice
Apc
D580/+ mice, a germline knockout strain derived from the Apc
conditional mice die primarily due to development of multiple
intestinal tumors [14]. We have found that these mice can
occasionally develop mammary tumors, as in Apc
Min/+ mice [8]
although at a low incidence (14.3%, 3 of 21). To further study the
role of Apc in mammary tumor development without being
hindered by the intestinal tumorigenesis, we induced Apc
mutations specifically in mammary epithelium using either K14
or WAP promoters. We have previously shown that homozygous
loss of Apc in K14-expressing embryonic cells results in abnormal
skin phenotype associated with aberrant development and
squamous metaplasia in many epithelial-derived tissues including
teeth and thymus, and die prior to weaning [14]. In contrast to
K14-cre; Apc
CKO/CKO mice, the K14-cre; Apc
CKO/+ mice were
phenotypically normal at birth, but upon aging showed decreased
survival primarily due to mammary tumor susceptibility in female
mice (Table 1, Figure 1A–G). The K14-cre; Apc
CKO/+ female mice
(n=19) had a median survival of 15-months. We were able to
carefully analyze 17 of these mice for pathology. The differences in
survival are statistically significant between the K14-cre; Apc
CKO/+
female mice and the cre-negative Apc
CKO/+ and Apc
CKO/CKO female
mice(p,0.02,logranktest).AlargeproportionofK14-cre;Apc
CKO/+
females invariably developed mammary tumors with focal squa-
mous metaplasia (13 of 17, 76.5%, Figure 1B–G) and the mice were
sacrificed when their tumors were over 2 cm in diameter. Of the
four mammary tumor-free female mice, three died of hepatoma,
histiocytic sarcoma and myxosarcoma, respectively and one
succumbed to severe dermatitis. We extensively performed a full
histological autopsy on seven mammary tumor-bearing mice, of
which two had lung metastasis. The mammary tumor susceptibility
was also observed in K14-cre; Apc
CKO/+ female mice backcrossed to
C57BL/6 (K14-cre; Apc
CKO/+-B6, n=8). At the time of analysis, half
of them (4 of 8, 50%) developed mammary tumors before reaching
12-months of age while the other half remained tumor-free for over
12-months.
Both WAP-cre positive heterozygous and homozygous Apc
CKO
mice were born in the expected Mendelian ratio with no bias
towards either sex. All mice were phenotypically normal at birth,
developed normally and were fertile. However, litters from WAP-
cre;Apc
CKO/CKO mothers could not thrive. When litters were
transferred to foster mothers, these litters survived and developed
normally, suggesting that it was due to lack of appropriate milk
production by WAP-cre;Apc
CKO/CKO mothers and consequent
inability to nurse their litters properly. This observation is in
agreement with the BLG-cre mediated inactivation of Apc [13].
Both WAP-cre positive heterozygous and homozygous Apc
CKO
female mice have been allowed to pass through four complete
lactation cycles with the exception of the two mice that underwent
three and were monitored up until they were 18-months of age.
Nulliparous females of the same genotypes were also monitored as
their controls. Unlike in the K14-cre;Apc
CKO/+ nulliparous female
mice that developed mammary tumors spontaneously, neither
mated WAP-cre positive Apc
CKO/CKO nor Apc
CKO/+ mice showed
mammary tumor susceptibility (Table 1). There were hardly any
differences in either the survival or tumorigenicity between
multiparous and nulliparous WAP-cre positive females of either
Apc
CKO genotypes and all of them lived as long as Cre negative
controls (Table 1). Mammary tumors were occasionally observed
in all four groups of WAP-cre positive females (Table 1).
Mammary tumors developed in two out of 14 (21.4%) WAP-
Author Summary
Breast cancer is one of the most common malignanices in
women in Western countries. Many components of Wnt/b-
catenin signaling pathway are known to play critical roles
in mammary tumor development, yet the role of the tumor
suppressor gene APC (adenomatous polyposis coli) in
breast oncongenesis is unclear. To study the role of Apc in
mammary tumorigenesis, we introduced conditional Apc
mutations specifically into two different mammary epithe-
lial populations using K14 (Keratin 14)-cre and WAP (Whey
Acidic Protein)-cre transgenic mice that express Cre
recombinase in mammary progenitor cells and lactating
luminal cells, respectively. In this study, we show that a
specific type of Apc somatic mutations in mammary
progenitor/stem cell population in mice induces mammary
carcinomas with histological and molecular heterogeneity,
but a complete deletion leads to squamous metaplasia.
Our data show that mutations in a multilineage progenitor
cell are important in certain mammary tumors. We also
show that certain Apc mutations are selected to achieve a
specific level of b-catenin signaling optimal for mammary
tumor development and explain partially the reason why
breast cancers do not develop as frequently as colorectal
tumors in patients that carry germline mutations in APC.
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CKO/+ female mice. (A) Survival Curve of K14-cre Apc
CKO/+ mice. Kaplan-Meier survival plot of
K14-cre; Apc
CKO/+ (red solid line, n=19), Apc
D580/+ (blue solid line, n=21), Apc
CKO/CKO (broken line, n=37) and Apc
CKO/+ mice (solid line, n=33).
Germline Apc heterozygous (Apc
D580/+) mice are predisposed to multiple intestinal tumorigenesis, but K14-cre driven Apc heterozygosity have
decreased survival compared to the controls primarily due to predisposition to mammary tumors. (B, C) A mammary tumor (C) from a K14-cre; Apc
CKO/+
female mouse (B) with grossly biphasic growth. Scale bar 1 cm. (D–G) K14-cre; Apc
CKO/+ tumors show a spectrum of histological patterns from
differentiated pilar (D), acinar (E), basosquamous (BS, F) to undifferentiated (UD, G), usually in combinations of these. Squamous metaplasia (arrows) is
frequent in these tumors, showing transdifferentiation to epidermal and pilar structures. Insets are the area within respective red boxes at higher
magnification. Scale bars 100 mm.
doi:10.1371/journal.pgen.1000367.g001
Table 1. Incidence of tumorigenesis in Apc mutant female mice.
Genotype Parity Age
Median Survival
Age/mo N
Mammary
tumors % (n)
Intestinal
tumors % (n)
Other
%( n )
Malignancy
%( n )
Cre Apc
K14-cre CKO/+ null 15.264.8 15.3 17 76.5 (13) 0 (0) 23.5 (4) 94.1 (16)
WAP-cre CKO/+ multi 18.362.5 18.9 6 16.7 (1) 0 (0) 0 (0) 16.7 (1)
WAP-cre CKO/CKO multi 18.062.7 19.2 14 14.3 (2) 0 (0) 21.4 (3) 35.7 (5)
WAP-cre CKO/+ null 17.664.3 18.7 8 12.5 (1) 0 (0) 25.0 (2) 37.5 (3)
WAP-cre CKO/CKO null 17.962.9 18.0 10 10.0 (1) 0 (0) 10.0 (1) 20.0 (2)
+ D580/+ null 5.461.0 5.8 21 14.3 (3) 100 (21) 0 (0) 100 (21)
+ CKO/+ - 18.763.7 19.0 33 3.0 (1) 0 (0) 6.0 (2) 9.1 (3)
+ CKO/CKO - 18.964.5 19.6 37 5.4 (2) 0 (0) 8.1 (3) 13.5 (5)
N=total number of mice in the study.
doi:10.1371/journal.pgen.1000367.t001
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CKO/CKO and one of 6 (16.7%) WAP-cre;Apc
CKO/+ multiparous
females, whereas those in nulliparous females were one of 10
(10%) and one of eight (12.5%), respectively.
Examination of mammary glands from the aged multiparous
WAP-Cre;Apc
CKO/CKO female mice revealed severe squamous
metaplasia in mammary glands that explains the inability of these
females to produce milk (Figure S1A, B), whereas those of the age
matched multiparous WAP-Cre;Apc
CKO/+, nulliparous WAP-
Cre;Apc
CKO/+ and nulliparous WAP-Cre;Apc
CKO/CKO females had
histologically virginal state without any acini development. The
extent of metaplasia was so severe in multiparous WAP-
Cre;Apc
CKO/CKO mice that almost all acini had squamous metapla-
sia, some with mineralization, showing osteometaplasia (Figure
S1B). This observation is analogous to BLG-cre-mediated inacti-
vation of Apc [13] and WAP-cre-mediated activation of oncogenic
b-catenin [12], further supporting that the homozygous mutations
of Apc in mammary epithelium perturbs normal mammary
differentiation and causes transdifferentiation, but does not readily
result in tumorigenesis. These results suggest the timing and
perhaps the cell type in which the Apc mutations occur is critical
for mammary tumor development.
Histological Heterogeneity and the Expression of both
Luminal and Myoepithelial Markers in K14-cre; Apc
CKO/+
Mammary Tumors but Not in WAP-Cre–Induced Apc
Mammary Tumors
Tumors arising from stem or progenitor cells may show mixed
lineage differentiation [15]. K14-expression starts embryonically, and
some of those cells give rise to both basal and luminal cells of
mammary gland [16], while WAP expression starts in adult luminal
mammary epithelium following pregnancy and lactation [17]. To
investigate whether Apc mutation-induced tumors arising from K14-
cre positive cells and WAP-cre positive cells have similar histology and
lineagedifferentiation,thesetumorswerehistologicallyexaminedand
stainedforbothK8,amarkerforluminalepithelialcells,anda-SMA,
K14 and p63, markers for basal myoepithelial cells.
The histology of mammary tumors that developed in the
germline knockout strain, Apc
D580/+ mice were similar to those
described for Apc
Min/+ mammary tumors [18]. All three of them
were pilar tumors with extensive keratinization, and were adjacent
to basosquamous components. The mammary tumors developed
in K14-cre; Apc
CKO/+ mice, either in mixed or C57BL/6
background, exhibited a variety of histological patterns within a
tumor similar to those found in other Wnt Pathway tumors [18].
Most of the tumors were adenocarcinomas with focal squamous
metaplasia (Figure 1B–G, 2). Squamous metaplasia may be
extensive as in pilar tumors or scattered as multiple foci. The
most common histological pattern observed in 16 K14-cre; Apc
CKO/+
mammary tumors from mice in the mixed background were acinar
(Figure 1E, 2A–E), often associated with basosquamous (Figure 1F,
2F–J) and pilar (Figure 1D, 2K–O) components but only
occasionally with undifferentiated component (Figure 1G, 2P–T).
Upon backcrossing to C57BL/6, the K14-cre; Apc
CKO/+ mammary
tumors (n=4) developed were primarily composed of basosqua-
mous and pilar histological types with extensive keratinization,
similar to Apc
D580/+ tumors, and acinar histology was no longer
observed. All K14-cre; Apc
CKO/+ mammary tumors exhibited
multiple histological patterns within a tumor, some more prominent
than the others. In two cases, the tumors appeared grossly biphasic
with distinct keratinized and solid portions (Figure 1B, C).
Histologically, the keratinized portion had pilar structures with a
number of keratinizing cysts (Figure 1D, 2K), and the solid cellular
portion had the acinar pattern (Figure 1E, 2A) when the tumor
derived from a mixed background K14-cre; Apc
CKO/+ mouse. A
similar biphasic growth was also observed in two mammary tumors
from K14-cre; Apc
CKO/+-B6 mice, but the solid portion had
basosquamous pattern. Immunochemical examination of these
tumors revealed that these tumors are composed of both luminal
and myoepithelial cells, with a-SMA and K14 positive myoepithe-
lial cells forming a single layer around the K8-positive tumor cells in
a well-organized structure as in normal ducts (Figure 2B–D, G–I).
The immunochemical patterns for K14 and K8 shifts to those of
epidermis inpilarstructures(Figure 2L–N).Onlyinundifferentiated
mammary tumor components, the expression of both lineage
markers was lost (Figure 2Q–S). These tumors were highly
proliferative as determined by Ki67 staining (Figure 2E, J, O, T),
although the proliferation pattern of the pilar tumors was restricted
to basal layer, analogous to that of hair follicles. Strong positivity for
Tcf/b-catenin target genes, Myc and cyclin D1, demonstrating the
activation of the Wnt/b-catenin pathway were also observed in
these tumors (Figure S2A–G). Like in many other mouse mammary
tumor models, K14-cre; Apc
CKO/+ mammary tumors were negative
for hormone receptors, Estrogen Receptor (ER) and Progesterone
Receptor (data not shown).
Most WAP-cre induced tumors, of which three were from WAP-
cre; Apc
CKO/CKO and two were from WAP-cre; Apc
CKO/+ mice, were
histologically acinar or glandular-like (Figure 2U–Y). Interestingly,
all except one were only positive for K8 and did not show defined
expression of myoepithelial markers, K14 and p63, as in K14-cre;
Apc
CKO/+ mammary tumors, and a-SMA expression was very
diffuse and aberrant (Figure 2V–X). They also had squamous
metaplasia where K14 expression is observed but with less defined
structures than those observed in K14-cre; Apc
CKO/+ tumors (Figure
S1C, D). These observations suggest that K14-cre; Apc
CKO/+
mammary tumors derived from either stem or progenitor cells of
the mammary gland while WAP-cre induced tumors derived from
more differentiated cells of mammary luminal cells.
Nature and Location of Second Hit Apc Mutations in K14
cre; Apc
CKO/+ Tumors
It is known that in Apc-mediated tumorigenesis, an important
initial event is the loss or mutation of the second copy of the Apc
locus. We examined the status of Apc in 20 K14-cre; Apc
CKO/+ (16
mixed, 4 C57BL/6 backgrounds) and five WAP-cre;Apc
CKO (both
WAP-cre;Apc
CKO/+ and WAP-cre;Apc
CKO/CKO) mammary tumors.
We performed 3 separate PCRs to respectively screen for the (i)
wild-type (320 bp) and Apc
CKO/+ (430 bp) alleles, (ii) wild-type,
Apc
CKO/+ and Apc
D580 (500 bp) alleles, and (iii) Apc
D580 allele alone
to genotype tumor DNA as shown in Figure 3A, i–iii. Skin and
mammary glands are the tissues known to have transgene
expression in K14-cre mice [16] and the presence of the deleted
allele of Apc can be detected in small quantities in normal
mammary glands of K14-cre; Apc
CKO/+ mice only by the Apc
D580
allele-specific PCR (Figure 3A iii; G1,G3). In contrast, most K14-
cre; Apc
CKO/+ tumors had Apc
D580/+ genotype, with no or reduced
presence of Apc
CKO allele (Figure 3A i and ii; T1,T3), showing
that these tumors were derived from the clonal expansion of
Apc
D580/+ cells. It is important to note that all K14-cre; Apc
CKO/+-
derived mammary tumors (20 of 20) were heterozygous for Apc
D580
mutation but still retained the wild-type allele and did not show
allelic loss. In WAP-cre positive Apc
CKO mice, the presence of the
Apc
D580 allele was only detected in multiparous WAP-cre;Apc
CKO
mammary glands (Figure S1E iii; G1,3, G6, G7) but none in
mammary glands of nulliparous WAP-cre;Apc
CKO females (Figure
S1E iii; G4, G5, G8, G9), confirming the specificity of the WAP
promoter. A single prominent Apc
D580 band was detected by 3-
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CKO
tumors irrespective of parity (Figure S1E ii; T5, T6, T7, T9),
demonstrating the complete conversion of the conditional allele to
the deleted allele. One WAP-cre;Apc
CKO/+ tumor from a multip-
arous female was heterozygous for Apc
D580 mutation with retention
of the wild-type allele (Figure S1E ii; T3) while the other from a
nulliparous female showed a reduced presence of the wild-type
allele, suggesting an allelic loss (Figure S1E ii; T5). Those tumors
that sporadically developed in cre-negative control mice were
negative for the Apc
D580 allele (Figure S1E iii; T), implicating that
their development was independent from Cre-induced Apc
mutation. These genotyping results were further supported by
RT-PCR of corresponding tumor RNA (data not shown).
To determine whether the inactivation of the remaining
functional Apc allele was achieved by intragenic truncation
mutations, we analyzed the tumor DNA by in vitro transcription
and translation (IVTT) assay. In view of prior mutational analyses
in humans and mice, the region of Apc considered most likely to
contain mutations is the first 3 kb of exon 15 [19,20]. All
mammary tumors that showed retention of the wild-type Apc allele
were analyzed by IVTT, and truncated Apc products were
detected in 19 of 20 (95%) K14-Cre; Apc
CKO/+ and all 3 (100%)
Apc
D580/+ mammary tumors, as well as in a single WAP-Cre;
Apc
CKO/+ mammary tumor that did not show loss of the wild-type
allele (Table 2). One sporadic Apc
CKO/+ mammary tumor
contained two distinct Apc mutations. The relevant PCR products
Figure 2. Histological heterogeneity in mammary tumors from K14-cre; Apc
CKO/+ female mice. (A–E) Acinar tumor. (F–J) Basosquamous
tumor with squamous metaplasia and ghost cells indicated by arrowheads. (K–O) Pilar tumor with extensive keratinization. (P–T) Undifferentiated
tumor. (U–Y) Mammary tumor from a multiparous WAP-cre; Apc
CKO/CKO female mouse. Stained with H&E for histology (A, F, K, P, U), K14 (B, G, L, Q, V),
a-SMA (C, H, M, R, W), K8 (D, I, N, S, X) and Ki67 (E, J, O, T, Y) antibodies as indicated at the top. Note the different patterns of cell lineage markers
associated with different tumor descriptors. Scale bars are 100 mm for K–O, the rest are 50 mm.
doi:10.1371/journal.pgen.1000367.g002
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identified are shown in Table 2.
When histologically distinct portions of a tumor were grossly
identifiable as in the tumor in Figure 1C, they were collected
separately and were analyzed by IVTT. It was found that they
shared the same somatic truncation mutation, further supporting
that these histologically distinct tumors derived from a clonal
expansion of the same progenitor cell that have acquired an Apc
truncation mutation (Figure 3B, T4&T5).
Most of mutations identified in mammary tumors were unique,
and were previously not detected in intestinal tumors from
Apc
1638N/+ heterozygous mice, with or without mismatch repair
deficiency [19,20]. All but four Apc truncation mutations detected
in K14-Cre; Apc
CKO/+ mammary tumors were frameshift mutations
(78.9%) of which two were intragenic deletions of over 10 bp.
Most notably, despite the variety of mutant sequences, most of the
mutations found were clustered further downstream, beyond
codon 1500, than the mutation cluster region of Apc mutations
(codons 850–1470) frequently found in mouse gastrointestinal
tumors [19,20] (Figure 3C). It is of interest to note that a sporadic
Apc
CKO/+ mammary tumor contained two distinct Apc mutations
that were located in very different regions of the Apc gene. One
mutation would result in a truncated product that lacks all the b-
catenin binding domains analogous to Apc
D580 mutation, while the
other was located in the same region where mutations in K14-Cre;
Apc
CKO/+ mammary tumors were found. These results indicate that
not only the inactivation of the remaining wild-type allele of Apc is
a pre-requisite in these tumors but there is also a selection for
particular types of Apc somatic truncation mutations that are likely
to result in some retention of down-regulating b-catenin signaling.
Figure 3. Somatic mutations in mammary tumors from K14-cre; Apc
CKO/+ mice. (A) Genotyping for Apc in K14-cre; Apc
CKO/+ mammary tumors
revealing that the conditional Apc allele has been recombined to the Apc
D580 allele. Genotyping PCR for the (i) wild-type and Apc
CKO/+ alleles, (ii) wild-
type, Apc
CKO/+ and Apc
D580 alleles, (iii) Apc
D580 allele alone. The faint presence of the Apc
D580 allele (500 bp band) in K14-cre; Apc
CKO/+ mammary glands
is only detectable by allele specific PCR (iii), whereas the corresponding mammary tumors shows the prominent presence of the deleted allele over
the Apc
CKO/+ allele (430 bp band) in 3-allele PCR (ii). Note that the wild-type allele (320 bp band) is still intact in all the mammary tumor samples.
Deleted Apc products are not detected in either liver or mammary tumors from K14-cre negative mice. L=Liver, G=Mammary Gland, MT or
T=Mammary Tumor. (B) Wild-type allele-specific in vitro transcription and translation assay of Apc for detection of truncation mutations. The majority
of tumors (19 of 20) showed truncated products (red arrows) within the analyzed region (codons 677–1674) of the remaining wild-type allele of Apc.
Note that two histologically distinct regions, acinar (T4) and pilar (T5) analyzed individually share the same mutations. (C) Distribution of Apc
mutations in K14-cre; Apc
CKO/+ mammary tumors. Diagram of Apc between codons 677 and 1674 showing positions and characteristics of truncation
mutations detected in K14-cre; Apc
CKO/+ (red) and Apc
D580/+ (blue) mammary tumors (above). The mutation distribution of Apc
1638N intestinal tumors
[50] is also shown for comparison (below). Each symbol, deletion (Empty triangle), insertion (filled triangle), substitution (pinhead), represents an
independent mutation. Note the mutation cluster region (MCR) of mammary tumors is located further downstream than the region frequently
observed in intestinal tumors. The three 15-aa (A,B,C) and four 20-aa (1, 2, 3, 4) b-catenin binding repeats and one SAMP repeat (S1) in this segment of
Apc are indicated. (D) Mutations in the K-ras and H-ras gene. Representative examples of somatic mutations in the K-Ras and H-Ras cDNA from
mammary tumors of the K14-cre; Apc
CKO/+ mice. Sequence chromatograms of codons 12, 13 and 61 are shown. Mutant peaks are indicated by arrows.
Mutations found in either K-Ras or H-Ras were mutually exclusive.
doi:10.1371/journal.pgen.1000367.g003
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CKO/+ Mammary
Tumors
Wnt1-induced mammary tumors frequently contain activating H-
Ras mutations [21] and mutations in K-Ras or N-Ras are frequently
found in c-Myc-induced tumors [22]. To determine whether
secondary somatic mutations in Ras are involved in Apc mutation-
induced mammary tumorigenesis, cDNA copies of tumor Ras
mRNAs were analyzed by direct sequencing. In our sequence-based
studies of 17 K14-cre; Apc
CKO/+,f i v eW A P - cre; Apc
CKO (Apc
CKO/CKO and
Apc
CKO/+ combined), and three Apc
D580/+ mammary tumors,
activating mutations were found at codons 12 and 61 of either H-
Ras or K-Ras only in a subset (7 of 17) of K14-cre; Apc
CKO/+ tumors but
none from other models.There were four mutationsinK-Rasand two
in H-Ras and these mutations were mutually exclusive (Figure 3D,
Table 3). It is of interest that, although the incidence is low, both H-
and K-Ras activation mutations were found in K14-cre; Apc
CKO/+
mammary tumors, since K-Ras mutations were frequently found in
Myc-induced mammary tumors but not H-Ras and vice versa in
MMTV-Wnt1 tumors. This further supports the molecular diversity as
well as the histological heterogeneity of K14-cre; Apc
CKO/+ mammary
tumors. H-Ras mutations were found in two of four tumors that were
predominantly of acinar histology, whereas K-Ras mutations were
found in tumors that either predominantly composed of undifferen-
tiated or mixed with undifferentiated histology (4 of 8). Sequence-
based analysis of exons 5 to 8 of the Tp53 gene was also carried out
but Tp53 missense mutations were not detected.
Comparative Analysis of Expression Profiles of K14-cre;
Apc
CKO/+ Mammary Tumors to Other Models
There are many mouse models of breast cancer that are
different in histopathology and possibly in cell of origin [23,24]
Table 2. Sequence of Apc mutations in various Apc heterozygous tumors.
Codon Mutation Consequence Wild-type Sequence
a K14-Cre; Apc
CKO/+ WAP-Cre; Apc
CKO/+ Apc
CKO/+ Apc
D580/+
924–928 14 bpD frameshift AGA AGC --- --A CAC TCA --1
b -
1466 +C frameshift GAG AGT GGG CCT AAG CAG 1- - -
1521 DAT frameshift GAT GTA GAAT TA AGA ATC --- 1
1528 CRTG l n RStop CCT CCA GTT CAG GAA AAC 1- 1
b -
1529 GRTG l u RStop GTT CAG GAA AAC GAC AAT 1- - -
1530 +A frameshift GTT CAG GAA AAC GAC AAT 2- - -
1530 DAC frameshift GTT CAG GAA AAC GAC AAT 1- - -
1534-1610 230 bpD frameshift AAT GGG A------ CCT GTG 1- - -
1542 GRTG l u RStop CAG CCT GAG GAA TCA AAT 1- - -
1546 GRTG l u RStop TCA AAT GAA AAC CAG GAT --- 1
1547 ACRT frameshift TCA AAT GAA AAC CAG GAT 1- - -
1547 +A frameshift TCA AAT GAA AAC CAG GAT 1- - -
1551 DA frameshift CAG GAT AAA GAG GTA GAA 1- - -
1553 GRTG l u RStop AAA GAG GTA GAA AAG CCT 1- - -
1554 +A frameshift GAG GTA GAA AAG CCT GAC 1- - -
1560-1565 14 bpD frameshift GAA AAA GA- --- -CT GAT 1- - -
1561 ART LeuRStop TCT GAA AAA GAC TTA TTA -1- -
1567 DC frameshift TCT GAT GAC GAT GAT ATT 1- - -
1567 DAC frameshift TCT GAT GAC GAT GAT ATT 1- - -
1568 +T frameshift TCT GAT GAC+GAT GAT ATT 1- - -
1568 DG frameshift TCT GAT GAC GAT GAT ATT 2- - -
1570 DT frameshift GAT GAT ATT GAA ATA TTA --- 1
19 1 2 3
aThe wildtype sequence surrounding each mutation is shown and the site of mutation is shown in bold.
bMutations found in the same mammary tumor.
doi:10.1371/journal.pgen.1000367.t002
Table 3. Histology and Ras mutations in mammary tumors.
Genotype Mammary Tumors N H-Ras K-Ras
K14-cre; Apc
CKO/+ Acinar/Glandular 6 2 (Q61L) 0
Basosquamous/Pilar 3 0 0
Undifferentiated 2 0 1 (Q61R)
Mixed 6 0 3 (G12D, G12V)
Total 17 2 4
Apc
D580/+ Basosquamous/Pilar 3 0 0
WAP-cre; Apc
CKO Acinar/Glandular 4 0 0
Mixed 1 0 0
Total 5 0 0
doi:10.1371/journal.pgen.1000367.t003
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[25,26]. To determine what types of mammary tumor models
K14-cre; Apc
CKO/+ mice represent, gene expression profiles of three
acinar-type mammary tumors, the most frequently found
histological pattern in K14-cre; Apc
CKO/+ in the mixed background,
and three cre-negative normal mammary gland samples were
determined using Affymetrix GeneChip M430 2.0 arrays. All 3
tumors were heterozygous for Apc
D580 mutation and the
remaining allele contained a truncation mutation in Apc. Both
Gene Set Enrichment analysis (GSEA) and Ingenuity Pathway
analysis (IPA) results indicated that mouse tumor profiles have
gene sets characteristics of cell cycle, cellular movement and
cancer related genes (Dataset S3, S4, S5, and S6). To get
additional insights into K14-cre; Apc
CKO/+ tumors, gene expression
data from our model was compared to data set of multiple mouse
mammary carcinoma models previously published [25]. Based on
mouse model intrinsic gene set cluster analysis [25], a
dendrogram and a heatmap were generated using dChip
(http://biosun1.harvard.edu/complab/dchip/) (Figure 4A–H).
The gene expression pattern in dendrogram showed more
correlations with luminal-type mammary tumors, which include
MMTV-Neu, MMTV-PyMT and WAP-Myc [25]. K14-cre; Apc
CKO/+
tumors also expressed genes that are strongly expressed in human
luminal tumors, such as XBP1 and luminal cell marker K8 and
K18, but were low in basal tumor-defining genes. These tumors
also showed high expression of Folate receptor 1 (Folr1), which is
commonly up-regulated in luminal tumor mouse models [25]. As
with most mouse mammary tumors, our model was also negative
for ER and many estrogen-regulated genes. In agreement with
these data, K14-cre; Apc
CKO/+ acinar-type mammary tumors
expressed K8 while K14 or a-SMA staining was restricted to a
myoepithelial pattern (Figure 2B–D).
To confirm the initial comparative results, we further compared
the gene expression of our K14-cre; Apc
CKO/+ model to those
previously published for MMTV-Neu, MMTV-Wnt1 and MMTV-
Wnt1/Neu bitrangenic mice [26]. A clustering diagram was
obtained that clustered tumors from MMTV-Neu, MMTV-Wnt1
and MMTV-Wnt1/Neu bitrangenic samples the same way as
indicated previously [26], with K14-cre; Apc
CKO/+ tumors clustering
in a separate cluster when hierarchical clustering analysis was done
by samples using rank correlation as distance measure for 19,581
probes. However if differentially expressed probes from K14-cre;
Apc
CKO/+ tumors versus controls were used for clustering, K14-cre;
Apc
CKO/+ tumors clustered next to MMTV-Neu with no effect on
clustering between MMTV-Neu, MMTV-Wnt1 and MMTV-Wnt1/
Neu samples. The same overall clustering was obtained using
mouse model intrinsic gene set [25] (Figure 4A–H). These results
support the view that acinar-type mammary tumors from K14-cre;
Apc
CKO/+ model are luminal type that correlate more with MMTV-
Neu than MMTV-Wnt1 model.
The elevated expression of Folr1 in mammary tumors detected
by microarray analysis was confirmed by quantitative real-time
RT-PCR. Since both the IPA and clustering analyses suggested a
potential involvement of Neu/Erbb2 (NM_001003817) in K14-cre;
Apc
CKO/+ mammary tumorigenesis (Figure S3A), we also included
Erbb2 in our analysis. Over 30-fold increase in Folr1
(NM_008034) expression compared to the control was detected
in acinar-type mammary tumors (108.7623.3 vs 3.161.1,
p=0.0051) confirming the microarray results, but non-acinar
type, including those tumors composed primarily of basosqua-
mous, pilar, and undifferentiated structures, and Apc
D580/+
mammary tumors showed no such differences (Figure 4I). There
were no significant differences between tumors and the control
for Erbb2 expression.
Discussion
To delineate the role of Apc mutations in mammary gland, we
used Cre-loxP technology to target inactivation of Apc gene in two
different mammary epithelial cells, using K14-cre and WAP-cre
transgenic mice. The Cre expression in our K14-cre transgenic
mice is driven by the basal K14 promoter, which is active in
progenitor cells that can give rise to both mammary luminal and
myoepithelial lineages [27,28], whereas that of WAP-cre trans-
genic mice is specific to lactating luminal epithelial cells [17]. The
availability of Apc mutant mice under two different mammary
promoters and their mammary tumors allowed us to study how
Apc loss contributes to mammary tumorigenesis. In this study, we
present several lines of evidence that target cells for Apc mutation-
induced mammary tumorigenesis are progenitor/stem cells and
that they require specific truncation mutations that partially retain
b-catenin down-regulating function. First, K14-cre induced Apc
D580
heterozygosity, but not WAP-cre induced Apc
D580 heterozygosity
or homozygosity, predisposes to mammary tumorigenesis. Second,
K14-cre mediated mammary adenocarcinoma showed mixed
lineage differentiation, in line with stem or progenitor cell origin,
in contrast to WAP-cre mediated tumors that comprised essentially
of luminal and abnormal a-SMA positive cells, lacking other basal
markers. This is further supported by the fact that two grossly and
histologically distinct regions of a tumor share the same somatic
Apc truncation mutation, suggesting their origin from a common
progenitor. Finally, the remaining wild-type allele of Apc is
inactivated not by allelic loss, which is the common mechanism
in intestinal tumorigenesis in Apc heterozygous mice, but
preferentially by somatic truncation mutations specifically in a
well defined region of the gene. This mutation cluster region was
different to the one reported for intestinal tumors, implicating that
the dosage-specific activation of downstream Wnt/b-catenin
signaling pathway is necessary for mammary tumorigenesis.
We have previously shown that K14-cre;Apc
CKO/CKO mice have
aberrant development and squamous metaplasia in many
epithelial-derived tissues and die perinatally [14], not allowing
the analysis of Apc loss in postnatal mammary gland. Analogous to
K14-driven Apc
D580 homozygosity, a complete inactivation of the
Apc gene in WAP-expressing mammary luminal epithelial cells
primarily led to the development of severe squamous metaplasia
but rarely neoplasia. These observations suggest that constitutive
activation of Wnt/b-catenin signaling pathway by Cre-mediated
Apc deficiency, resulting in homozygous Apc (Apc
D580/D580)
mutations, invariably induce terminal squamous transdifferentia-
tion of the mammary epithelium irrespective of cell origin of
mutated cell, but do not develop tumors. This is in agreement with
other Cre-mediated Wnt/b-catenin activation models in which
induction of squamous metaplasia but not neoplasia was primarily
observed [12,13,29].
Although homozygous Apc (Apc
D580/D580) mutations induced
either by K14 or WAP-promoters invariably results in squamous
metaplasia, Cre-mediated Apc heterozygosity (Apc
D580/+)i nK14-cre;
Apc
CKO/+ mice developed mammary tumors with high penetrance.
A similar tendency was also observed in K14-cre; Apc
CKO/+ mice
backcrossed to C57BL/6, suggesting that the initiation of Apc-
mediated mammary tumorigenesis is not affected by the genetic
background. The majority of mammary tumors developed in K14-
cre; Apc
CKO/+ mice had Apc
D580/+ genotype and have somatically
acquired truncation mutation in the remaining wild-type allele,
unlike intestinal tumors in Apc
D580/+ mice and other germline Apc
heterozygotes in which the preferential mechanism of the wild-
type Apc is allelic loss [14,30–32]. Most intriguingly, these
truncation mutations were clustered around codon 1530 of Apc
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CKO/+ mammary tumors to MMTV-Wnt1 and MMTV-Neu tumors. (A)
Dendrogram of K14-cre; Apc
CKO/+, MMTV-Wnt1, MMTV-Neu and MMTV-Wnt1/Neu tumors [26], based on hierarchical clustering analyis of Affymetrix
microarray data. K14-cre; Apc
CKO/+ acinar mammary tumors (tumor 1, 2, 3) showing more correlation to MMTV-Neu. (B–G) Mouse models intrinsic gene
set cluster analysis, as depicted in Herzchkowitz et al [25]. Red and blue indicate expression levels respectively above and below the median. The
magnitude of deviation from the median is represented by the color saturation. (B) Luminal epithelial gene expression pattern. (C) Genes encoding
components of basal lamina. (D) A second basal epithelial cluster genes. (E) Genes implicated in epithelial to mesenchymal transition. (F) A second
mesenchymal cluster that is expressed in normal. (G) Estrogen-regulated genes. (H) Potentially estrogen-regulated genes. (I) Real-time RT-PCR
analysis of Folr1 and Erbb2 transcript levels in mammary tumors of the K14-cre; Apc
CKO/+ and Apc
D580/+ mice. Bars represent the mean values6S.E.M.
for 7 control mammary glands (MG), 12 acinar and 6 non-acinar (undifferentiated or basosquamous) K14-cre; Apc
CKO/+ and 4 Apc
D580/+ (d580)
mammary tumors normalized to the Hprt1 transcript levels. The difference in the Folr1 transcript levels was statistically significant between the
control only in the acinar-type K14-cre; Apc
CKO/+ mammary tumors (p,0.006), whereas no difference was detected for the Erbb2 transcript levels
between the tumors and the control.
doi:10.1371/journal.pgen.1000367.g004
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mutation cluster region typically observed in both human and
mouse intestinal tumors [19,20,33]. Regulation of intracellular b-
catenin levels is thought to represent one of the most important
functions of the Apc tumor suppressor protein. Three different
motifs in the central region of Apc are responsible for this activity.
The three 15-amino acid (aa) repeats that bind b-catenin, the
seven 20-aa repeats that both bind and down-regulate b-catenin
[34,35], and the three SAMP motifs that bind conductin/axin
[36,37]. The mutations found in mammary tumors would result in
truncated Apc polypeptides retaining up to three of the seven 20-aa
repeats but lack all SAMP motifs. It has been shown that loss of these
functional motifs, especially those that lead to the elimination of at
least five of the seven 20-aa repeats greatly reduced the b-catenin
down-regulation activity of Apc [38]. However, Smits et al [39]
showedthathaploinsufficiency for thetruncated Apc polypeptide that
retains up to the third 20-aa repeat (Apc
1638N/1572T) still retained some
b-catenin down-regulation activity, resulting in a 5-fold increase in
the transcriptional activity compared to a 30-fold increase in Apc
mutation homozygosity (Apc
1638N/1638N).
Since dosage of b-catenin is critical in determining epithelial cell
fate in many organs and varying the level of b-catenin signaling
during a cell fate program have been shown to switch the epithelial
cell fate [40], it is possible that the homozygosity of Apc mutation
(Apc
D580/D580) results in too much b-catenin transcriptional
activity, that may push cells into the signaling events that leads
to squamous transdifferentiation rather than to hyperplasia of
mammary epithelial cells and eventually to neoplasia. The Apc
D580
heterozygosity with somatic mutation of the remaining wild-type
Apc allele that retains some b-catenin down-regulating domains
may lead to the optimal dosage of b-catenin necessary for
mammary tumorigenesis. Indeed, Apc
D580/D580 homozygosity
induced by K14 promoter resulted in severe squmaous metaplasia
and ectopic hair follicle morphogenesis in many organs including
skin and thymus [14] and the current data using WAP-cre also
resulted in squamous metaplasia in mammary glands rather than
tumor development. Since mutations found in mouse intestinal
tumors result in either allelic loss or a somatic truncation mutation
upstream of the third 20-aa repeats [14,19,20,30–32], deletion of
all the b-catenin binding domains seems to confer the main
selective advantage in mouse intestinal tumorigenesis. Thus, our
results and those of others indicate that there is an Apc-regulated
level of b-catenin signaling optimal for tumor formation that
differs tissue-specifically. The selection for an optimal b-catenin
signaling level for tumor formation is also supported by the
spectrum of somatic mutations observed in colorectal adenomas
from Familial Adenomatous Polyposis (FAP) patients with different
germline mutations in APC [41]. Our data also partly explain why
breast cancers do not develop as frequently as colorectal tumors in
FAP patients. It is likely that unless somatic truncation mutation
optimal for breast oncogenesis is acquired in the APC gene,
mammary epithelial cells are not initiated towards tumorigenesis
but instead become metaplastic. Such selection would reduce the
incidence of tumorigenesis and require much longer latency, as
demonstrated by Apc
D580/+ and K14-cre; Apc
CKO/+ mouse models.
Our histopathological and molecular analyses showed that the
majority of K14-cre;Apc
CKO/+ mammary tumors are adenocarcino-
mas with multiple foci of squamous metaplasia. These tumors are
highly proliferative, ER-negative carcinomas, showing strong
positivity for Tcf/b-catenin target genes, Myc and cyclin D1,
with expression of both luminal and basal epithelial markers. They
have many histological features common to Wnt pathway tumors
previously described [18], but at the same time have expression
profiles that correlate more to luminal tumor models. The latter
observation could be explained partly by the predominance of
acinar-type histology, which is a luminal type histology, found in
the majority of K14-cre;Apc
CKO/+ tumors from the mixed back-
ground and was the histological type selected for the expression
analysis in the current study. The selection of this particular
histological type may have biased the expression profiles towards
luminal expression pattern. Interestingly, the frequency of the
acinar-type histology diminished and basosquamous/pilar struc-
tures predominated in the K14-cre;Apc
CKO/+-B6 tumors. Since
either histological type of mammary tumors had the same
mechanism of Apc inactivation irrespective of the genetic
backgrounds, it suggests that the mode of initiation is the same
but the progression to certain histological types is greatly
influenced by modifier genes associated with the genetic
backgrounds.
Comparison of our gene expression profiling data to published
mouse and human breast cancers suggests that acinar-type tumors
from K14-cre;Apc
CKO/+ mice are more similar to luminal type
mouse models [25]. The similarities between mouse and human
luminal tumors are limited by the fact that most human luminal
epithelial cluster contains the ER and many estrogen-regulated
genes, but many mouse mammary tumors, including K14-
cre;Apc
CKO/+ tumors, are ER-negative. However, the expression
profiles of K14-cre;Apc
CKO/+ acinar tumors also included a human
luminal tumor-defining gene, XBP1 [42,43] and stained positive
for K8. Our tumor set also showed elevated expression of Folr1,
which is a gene included in luminal epithelial gene expression
cluster that is highly expressed in MMTV-PyMT, MMTV-Neu,and
WAP-myc tumors [25]. It was of interest that Folr1 expression level
varied within K14-cre;Apc
CKO/+ mammary tumors depending on
histology, and the ones that had elevated expression were those
predominantly composed of acinar histology. The tumors from
Apc
D580 mice, which were of pilar and basosquamous histology,
had very low Folr1 expression level. Although Folr1 is not
associated with human luminal tumors, its overexpression and
poor prognosis have been implicated in human breast cancers
[44,45].
To determine whether other oncogenic pathways are involved
in Apc mutation-induced mammary tumorigenesis, we examined
the status of Ras oncogenes and Tp53 in these tumors. It has been
previously shown that c-Myc induced mammary tumors in mice
frequently harbor spontaneous activating mutations in K-Ras [22]
while over 50% of MMTV-Wnt1 tumors contain oncogenic
mutations in H-Ras [21]. Jang et al also suggested that K-Ras
activation strongly synergizes with both c-Myc and Wnt1 in
mammary tumorigenesis and promotes the progression of tumors
to oncogene independence, while H-Ras mutant Wnt1-induced
tumors remain oncogene dependent [46]. It is of interest that
although their presence was mutually exclusive to each other, both
H-Ras and K-Ras oncogenic mutations were found in a subset K14-
cre;Apc
CKO/+ tumors. We could not find a strong association
between histology, incidence of lung metastasis and Ras mutations,
but those tumors that contained K-Ras mutations frequently had
heterogeneous histology containing aggressive looking undifferen-
tiated regions that have lost both lineage markers while those with
H-Ras mutations were predominantly of acinar-type.
In conclusion, our study demonstrates that activation of Wnt/b-
catenin signaling via inactivation of Apc leads to mammary
tumorignesis when the inactivation takes place in mammary
epithelial progenitor cells rather than more differentiated secretory
luminal cells; and when somatic truncation mutation is acquired in
a particular region of the Apc gene, which may be necessary to
achieve a certain level of b-catenin signaling activation required
for mammary tumorigenesis. These initiated tumor cells develop
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each with different expression pattern of lineage markers, some
acquiring more oncogenic mutations, such as in either H-Ras or K-
ras genes. Our data indicate that only a specific subset of somatic
mutations at the Apc gene will successfully lead to tumor formation
in the mammary epithelium and there is a selection for Apc
mutations that retain some down-regulating activity of b-catenin
signaling. We propose that this selection is aimed at a specific level
of b-catenin signaling optimal for mammary tumorigenesis, rather
than at its constitutive activation achieved by deletion of all the b-
catenin down-regulating domains in Apc, which invariably results
in squamous metaplasia.
Materials and Methods
Mammary-Specific Inactivation of Apc
The Apc conditional (Apc
CKO) and germline (Apc
D580)k n o c k o u t
mice, WAP-cre and K14-cre transgenic mice have previously been
described [14,16,17]. Apc
D580/+ mice have already been backcrossed
to C57BL/6 background. The rest of the mice analyzed in this study
were generated as follows: Apc
CKO heterozygote mice of the F1
generation (C57BL/66129/S background) were first crossed with
either WAP-cre mice (C57BL/6 background) or K14-cre transgenic
mice (FVB background). Cre-positive Apc
CKO/+ male mice thus
generated were then crossed with Apc
CKO/CKO females to generate
homozygous and heterozygous Apc
CKO offspring either with or
without respective cre t r a n s g e n e .T h em i c ew e r ei n t e r c r o s s e d
thereafter for maintenance. Subsequently, K14-cre; Apc
CKO/+ female
mice backcrossed for 4 generations to achieve .95% C57BL/6J
background were also included in the analysis so that the results
between two different promoters will be comparable. Females with
genotypes WAP-cre; Apc
CKO/+ and WAP-cre; Apc
CKO/CKO were mated
and undergone pregnancies 4 times to facilitate WAP-cre-mediated
deletion of exon 14 of Apc gene. Mice with genotype K14-cre;
Apc
CKO/CKO are perinatally lethal [14] and phenotypically normal
K14-cre; Apc
CKO/+ littermates were used for analysis. The mice were
sacrificed when either they were moribund or their tumors reached
at least 2 cm in diameter, following Institutional Animal Care and
Use Committee guidelines.
Genotyping of Mice
Mouse tails tips obtained at ,10 days of age were lysed
overnight in DirectPCR Lysis Reagent (Viagen Biotech) contain-
ing 0.1 mg/ml Proteinase K (Qiagen). The crude lysates were
incubated at 85uC for 45 minutes and 0.5 ml of lysate was directly
used per 25 ml PCR reaction. Detection of various Apc alleles and
cre transgene was carried out as previously described [14].
Histological Analysis
Mice were sacrificed by CO2 inhalation when they developed
gross tumors or were moribund. The location and size of tumors
were routinely recorded and pictures were taken from each mouse.
Tumors were cut in portions and a portion was either fixed in 10%
netural buffered formalin (NBF) or in 4% paraformaldehyde. The
other portion was either snapped frozen in liquid nitrogen or
immersed in RNAlater solution (ambion) overnight and stored at
280uC until molecular analyses. Mammary glands were also
collected routinely from each mouse: 4
th mammary gland was
fixed flat on a piece of paper towel in 10% NBF, 9
th mammary
gland for whole mount and either 8
th and 3
rd tumor-free
mammary gland was collected for molecular analyses. The mice
were then dissected for gross examination. A portion of liver and
lungs were similarly collected and fixed. Then the whole body was
fixed in Bouin’s solution. The fixed tissue samples were then
submitted to Rodent Histopathological Core, processed and
embedded in paraffin. Tissue sections were cut and stained with
H&E for histopathological examinations.
Immunohistochemistry
Five-mm sections were cut from the paraffin-embedded tissues
and immunohisochemistry was performed essentially as previously
described [14]. Briefly, sections were deparaffinized, rehydrated
and boiled in either Citrate buffer (10 mM, pH 6) or Tris buffer
(10 mM Tris, 1 mM EDTA, pH 9) for antigen retrieval. Slides
were than treated with 3% peroxidase in PBS, followed by
blocking in normal horse serum. Primary antibodies against Ki67
(1:200, Vector Laboratories), b-catenin (1:200, BD Transduction
Lab), cyclin D1 (1:100, Lab Vision), c-myc (1:200, Upstate),
esterogen receptor ERa and progesterone receptor (1:2000, 1:500,
respectively, Santa Cruz) and cellular markers such as cytokeratins
K1, K6, K14 (1:1000, 1:500, 1:2000, respectively, Covance), K8
(1:100, TROMA-I, DSHB), p63 (1:200, Chemicon International)
and a-smooth muscle actin (a-SMA, 1:800, Sigma) were applied
followed by an incubation with biotin-conjugated appropriate
secondary antibody. Mouse-on-Mouse kit (Vector Laboratories)
was used with the mouse primary antibodies. The Vectastain Elite
ABC kit and DAB (Vector Laboratories) were used for detection,
following manufacturer’s instructions.
Mammary Gland Wholemount
This procedure was carried out as described on the mammary
gland website: http://mammary.nih.gov.
DNA and RNA Extraction from Tumors
Both genomic DNA and RNA from tumors and various tissue
samples collected at the time of autopsy were extracted as
described previously [14]. Briefly, genomic DNA was extracted
using DNeasy mini kit (QIAGEN). RNA was extracted by
homogenizing tumors and tissues in 3 ml Trizol reagent (Invitro-
gen). After phase separation, an equal volume of 70% ethanol was
added to the aqueous phase and purified through PureLink Micro-
to-Midi Total RNA Purification System (Invitrogen), following
manufacturer’s instruction. Concentrations of nucleic acids were
determined by Nanodrop (Ribogreen, Molecular Probes, Eugene,
Oregon, United States).
Analysis of Apc Status in Tumors
Tissue-specific recombination of the conditional alleles in
tumors and various tissue samples was examined by analyzing
both their extracted DNA and RNA as described previously [14].
Briefly, genomic DNA samples were examined by a semi-
quantitative 3-primer genotyping PCR that will give 3 distinct
sized products from the wild-type (320 bp), conditional (430 bp)
and deleted (500 bp) alleles of Apc. In addition, two separate 2-
primer PCRs were performed; one to check for the wild-type and
Apc
CKO alleles and the other to detect the presence of the Apc
D580
allele alone. The expression of full-length and truncated Apc alleles
were examined by performing RT-PCR on RNA using Super-
Script One-Step RT-PCR with Platinum Taq (Invitrogen),
following manufacturer’s protocol.
Upon confirmation of the retention of the wild-type Apc allele,
codons 677–1674 of the mouse Apc gene were analyzed for
truncation mutations by PCR and in vitro transcription and
translation (IVTT) assay as described previously [20,47] but with
some modifications. All DNA amplifications were performed using
Pfu Ultra II fusion HS DNA polymerase (Stratagene) according to
manufacturer’s instruction. The wild-type allele-specific amplifi-
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amplification of deleted Apc
D580 allele using the forward primer 59-
CATTCTCCCCTACTTAGATGG and a reverse primer 59-
GTTGTCATCCAGGTCTGGTG in the first PCR reaction.
Two overlapping segments of the Apc gene covering codons 677–
1234 and 1100–1674 were subsequently amplified from aliquots of
the first reactions using two pairs of PCR primers specific for
IVTT. Cycling conditions for the first stage PCR were one cycle of
94uC for 2 min, followed by 20 cycles of 94uC for 20 s, 58uC for
20 s and 72uC for 90 s, with one final extension cycle at 72uC for
3 min. Cycling conditions for the second stage PCR were as above
except the cycle number was increased to 25. The PCR products
were directly used for IVTT assay as described previously [20,47].
In order to facilitate the detection of Apc truncation mutations
from tumor samples that are frequently co-harvested with adjacent
normal tissues, we developed a method based on expression of
Apc-GFP fusion polypeptides in bacteria, in which colonies
derived from PCR products with mutation appear GFP-negative.
The pTrcHis B Prokaryotic Expression Vector (Invitrogen) was
modified to contain GFP coding sequence (Acc# U87625)
between NheI and SacI sites. The sequence between NcoI and
NheI sites, coding poly-histidine region was replaced with a
BamHI site, such that insertion of amplified Apc fragments
between BamHI and NheI sites restores the reading frame of
GFP. For characterization of tumor-specific mutations, the PCR
products were digested with BamHI and NheI, gel purified, and
cloned into modified pTrc vector and transformed into bacterial
cells using standard cloning procedures. Transformed bacterial
cells were spread on LB plates containing final concentrations of
50 mg/ml ampicillin and 50 mM IPTG and incubated overnight at
37uC. The numbers of non-fluorescent and fluorescent colonies
were counted under long-wave length UV light. When the
percentage of non-fluorescent colonies over total was above the
control level, individual GFP negative clones were screened by
IVTT to identify mutations, and their DNA sequences were
determined.
Tp53 and Ras Mutational Analysis
For p53 mutational analysis, exons 5 to 8 of Tp53 were
examined by performing RT-PCR on RNA using primers p53-
F117 and p53-R313 and SuperScript One-Step RT-PCR with
Platinum Taq (Invitrogen). The PCR products were then
sequenced by nested primers, p53-F121 and p53-R308. For K-
Ras and H-Ras codons 12, 13 or 61 mutation analysis, RNA was
first reverse-transcribed and amplified using SuperScript One-Step
RT-PCR system, followed by nested-PCR using Pfu Ultra II
fusion HS DNA polymerase (Stratagene). The mutations were
scored positive when approximately half of the resulting amplified
DNA had the same mutation, and when the results were
confirmed by either sequencing from both ends or by sequencing
corresponding genomic amplified products. Sequences of primers
used in the study are listed in Table S1.
Gene Expression Profiling
Total RNA (5–10 mg) extracted from 3 acinar-type mammary
tumors and 3 age-matched control mammary glands from cre-
negative mice were hybridized and scanned to GeneChip M430
2.0 according to Affymetrix protocols (Affymetrix). Scanned
microarray images were imported into GeneChip Operating
Software (GCOS, Affymetrix) to generate signal values and
absent/present calls for each probe-set using the MAS 5.0
statistical expression algorithm (.chp files). Each array was scaled
to a target signal of 500 using all probe-sets and default analysis
parameters. Prior to performing any other analysis Affymetrix
detection calls were used to remove 12,844 probes which had
‘Absent’ call across all samples. Data set with 32,322 probes was
used as starting point for any subsequent analysis. To identify
genes differentially expressed between tumor and control samples
two-sample t-test was used (Dataset S1). T-test was performed
using ComparativeMarkerSelection module of Gene Pattern
(http://www.broad.mit.edu/cancer/software/genepattern/) [48].
Based on two-sample t-test results, any probes with fold differences
below 2, t-test values below 4.5 were removed and only the probes
that have either consistent absent or present calls were used as
input for Ingenuity Pathway Analysis (IPA) Software (http://www.
ingenuity.com/, Dataset S2). Ingenuity core analysis generated
over 60 networks with nearly 600 network nodes in total, many of
them involved in cell cycle, cell, growth, cell death, DNA
replication, and cancer (Dataset S3, S4, S5, and S6).
Gene Set Enrichment Analysis (GSEA) was performed using
java GSEA http://www.broad.mit.edu/gsea/ as previously de-
scribed [49]
Comparison of Gene Expression Profiles with Other
Mouse Models
To get additional insights in K14-cre; Apc
CKO/+ tumors, gene
expression from our mouse model was compared to data set of
multiple mouse mammary carcinoma models and human breast
tumors previously published [25]. In particular, based on genes
mainly in intrinsic gene set cluster analysis of mouse models a
dendrogram was generated using dChip (http://biosun1.harvard.
edu/complab/dchip/) (Figure 4A).
To further compare gene expression of K14-cre; Apc
CKO/+ model,
gene expression probe level data (CEL files 430A 2.0) from Shixia
Huang et al. for tumors from MMTV-Wnt1, MMTV-Neu and
MMTV-Wnt1/MMTV-Neu bitransgenic mice were obtained [26].
MAS5.0 algorithm was used to estimate probe expression. Since
430 2.0 chips have additional probe sets compared to 430A 2.0 the
subset corresponding to 430A 2.0 was used for MAS5.0 global
method of scaling/normalization. Target Intensity value of 500
was used for all arrays. Prior to performing any other analysis,
Affymetrix detection calls were used to remove 3,045 probes which
had ‘Absent’ call across all samples. Data set with 19,581 probes
was used as starting point for any subsequent analysis. Hierarchi-
cal clustering by samples was performed using data for all 19,581
probes as input and rank correlation as (Figure S3B). Subsequent-
ly, 1,335 differentially expressed probes (fold differences above 2, t-
test values above 4.5) from K14-cre; Apc
CKO/+ tumors versus
controls were used for clustering analysis (Figure S3C).
Real-Time RT-PCR
The expression levels of Folr1 and Erbb2 in 17 K14-cre; Apc
CKO/+,
5 WAP-cre; Apc
CKO (Apc
CKO/CKO and Apc
CKO/+ combined), 4
Apc
D580/+ mammary tumors were compared to those of 7 normal
mammary glands by quantitative RT-PCR with HPRT1 as an
internal control. Most of K14-cre; Apc
CKO/+ mammary tumors in
the mixed background consisted of acinar-type, but there were a
few which had distinct histology. Therefore, tumors were roughly
divided into 2 groups; acinar and non-acinar. The latter group of
mammary tumors primarily composed of undifferentiated, basos-
quamous and pilar-type histology. We analyzed 14 acinar-type,
and 8 non-acinar type. The mammary tumors developed in
Apc
D580/+ mice were mostly of basosquamous-type. TaqMan Gene
Expression Assays for respective genes were used on 7500 Fast
Real-Time PCR System (Applied Biosystem) according to the
manufacturer’s protocol. Relative quantity was calculated using
Sequence Detection Software version 1.4 (Applied Biosystem).
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Figure S1 WAP-cre induced inactivation of Apc. (A) Whole-
mount of a mammary gland showing development of severe
squmaous metaplasia in multiparous WAP-cre; Apc
CKO/CKO female
mouse. (B) H&E staining of another gland from the same mouse
showing multiple metaplstic lesions throughout the gland. (C)
H&E staining of a mammary tumor from a multiparous WAP-cre;
Apc
CKO/CKO female mouse with squamous metaplasia (arrows)
which have less defined structures than those in K14-cre; Apc
CKO/+
tumors. (D) K14 expression was only observed in these metaplstic
lesions in WAP-cre induced tumors. Scale bars: 50 mm. (E)
Genotyping for Apc in WAP-cre positive mammary glands and
tumors, showing WAP-cre and parity-specific recombination of
conditional alleles. Genotyping PCR for the (i) wild-type and
Apc
CKO/+ alleles, (ii) wild-type, Apc
CKO/+ and Apc
D580 alleles, (iii)
Apc
D580 allele alone. The presence of the Apc
D580 allele detected in
mammary tumors from nulliparous WAP-cre positive females
demonstrates that these tumors have derived from a clone of cells
that have undergone Cre-mediated recombination.
Found at: doi:10.1371/journal.pgen.1000367.s001 (3.0 MB PPT)
Figure S2 Expression of Tcf/b-catenin-target genes in mam-
mary tumors from K14-cre; Apc
CKO/+ female mice. A representative
acinar-type mammary tumor stained with H&E for histology (A),
luminal marker K8 (B), basal marker K14 (C) and b-catenin (D),
showing strong positivity for Tcf/b-catenin-target genes cyclin D1
(E) and c-myc (F, G). Examples of cells with strong c-myc positivity
are indicated by arrows (G). Scale bars: 50 mm for (A–F), 25 mm
for (G).
Found at: doi:10.1371/journal.pgen.1000367.s002 (7.8 MB PPT)
Figure S3 Ingenuity Pathway and Hierarchical Clustering
analyses of expression profiles of K14-cre; Apc
CKO/+ mammary
tumors. (A) A representative IPA network. Ingenuity core analysis
generated over 60 networks, many of them involved in cell cycle,
cell, growth, cell death, DNA replication and cancer (see Dataset
S3 for information for all networks). A representative network is
shown, showing elevated expression of Folr1. Green for elevated
expression in tumor and red for elevation in control. (B)
Hierarchical clustering by samples for 19,581 probes. A clustering
diagram of K14-cre; Apc
CKO/+ tumors (1107 E,F,H), controls (1107
A,C,D), tumors from MMTV-Wnt1, MMTV-Neu and MMTV-
Wnt1/MMTV-Neu bitransgenic mice. Rank correlation was used as
distance measure. (C) Hierarchical clustering by samples for 1,335
probes. 1,335 differentially expressed probes (fold differences
above 2, t-test values above 4.5) from K14-cre; Apc
CKO/+ tumors
versus controls were used.
Found at: doi:10.1371/journal.pgen.1000367.s003 (0.5 MB PPT)
Table S1 Primer Sequences for Tp53 and Ras Mutational
analysis.
Found at: doi:10.1371/journal.pgen.1000367.s004 (0.05 MB
DOC)
Dataset S1 Differential gene expression between tumors and
control samples. Information on differential gene expression
between tumors and control samples for 32,322 probes.
Found at: doi:10.1371/journal.pgen.1000367.s005 (21 MB XLS)
Dataset S2 Input list of probes for Ingenuity Pathway Analysis.
Information for 2,800 probes which were used as input for IPA.
Out of data set with 32,322 probes that have been analyzed for
differential expression by Gene Pattern, probes with fold
differences below 2, t-test values below 4.5 were removed and
only the probes that have either consistent absent (a) or present (p)
calls, but not absent across all samples, i.e., ppp-ppp, aaa-ppp or
ppp-aaa were used as input for Ingenuity Pathway Analysis
Software. Overall 2,800 probes were used as input for IPA.
Found at: doi:10.1371/journal.pgen.1000367.s006 (2.7 MB XLS)
Dataset S3 Networks generated by Ingenuity Pathway Analysis.
Information for all networks generated by Ingenuity Pathway
Analysis.
Found at: doi:10.1371/journal.pgen.1000367.s007 (0.04 MB
XLS)
Dataset S4 Molecules used in networks generated by Ingenuity
Pathway Analysis. Information for all molecules used in networks
generated by Ingenuity Pathway Analysis.
Found at: doi:10.1371/journal.pgen.1000367.s008 (0.7 MB XLS)
Dataset S5 Canonical Pathways. Information for Canonical
Pathways identified by Ingenuity Pathway Analysis.
Found at: doi:10.1371/journal.pgen.1000367.s009 (0.05 MB
XLS)
Dataset S6 Functions. Information on processes identified by
Ingenuity Pathway Analysis.
Found at: doi:10.1371/journal.pgen.1000367.s010 (0.2 MB XLS)
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